CTI BIOPHARMA CORP (CTIC) 5.72 -0.1 (-1.72%)
5.72 -0.1 (-1.72%)
US12648L6011 - Common Stock - After market: 5.72 0 (0%)
Buy % Consensus
Analysts have set a mean price target of 11.64. This target is 103.48% above the current price.
CTIC was analyzed by 15 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about CTIC.
In the previous month the buy percentage consensus was at a similar level.
CTIC was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target
Up and Down Grades
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-10-17 | SVB Leerink | Initiate | Outperform |
| 2022-09-01 | JP Morgan | Initiate | Buy |
| 2022-09-01 | Jefferies | Initiate | Buy |
| 2022-08-09 | JMP Securities | Maintains | Market Outperform |
| 2022-08-09 | Needham | Maintains | Buy |
| 2022-07-07 | Cowen & Co. | Initiate | Outperform |
| 2022-03-02 | JMP Securities | Maintains | Market Outperform |
| 2022-03-02 | Needham | Maintains | Buy |
| 2021-12-01 | Needham | Maintains | Buy |
| 2021-08-09 | BTIG | Initiate | Buy |
| 2021-05-06 | Stifel | Initiate | Buy |
Analyst Ratings Stock Screener Links
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA